Rewriting DNA Methylation Signatures at Will:The Curable Genome Within Reach? by Stolzenburg, Sabine et al.
  
 University of Groningen
Rewriting DNA Methylation Signatures at Will





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Stolzenburg, S., Goubert, D., & Rots, M. G. (2016). Rewriting DNA Methylation Signatures at Will: The
Curable Genome Within Reach? In A. Jeltsch, & R. Z. Jurkowska (Eds.), DNA Methyltransferases: Role
and Function (Vol. 945, pp. 475-490). (Advances in Experimental Medicine and Biology; Vol. 945). Springer
International Publishing. https://doi.org/10.1007/978-3-319-43624-1_17
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
 Rewriting DNA Methylation Signatures 
at Will: The Curable Genome Within 
Reach? 
 
Sabine Stolzenburg, Désirée Goubert, 





Epigenetic regulation of gene expression is vital for the maintenance of genome 
integrity and cell phenotype. In addition, many different diseases have underly- 
ing epigenetic mutations, and understanding their role and function may unravel 
new insights for diagnosis, treatment, and even prevention of diseases. It was an 
important breakthrough when epigenetic alterations could be gene-specifically 
manipulated using epigenetic regulatory proteins in an approach termed epigen- 
etic editing. Epigenetic editors can be designed for virtually any gene by target- 
ing effector domains to a preferred sequence, where they write or erase the 
desired epigenetic modification. This chapter describes the tools for editing DNA 
methylation signatures and their applications. In addition, we explain how to 
achieve targeted DNA (de)methylation and discuss the advantages and disadvan- 
tages of this approach. Silencing genes directly at the DNA methylation level 
instead of targeting the protein and/or RNA is a major improvement, as repres- 
sion is achieved at the source of expression, potentially eliminating the need for 
continuous administration. Re-expression of silenced genes by targeted demeth- 
ylation might closely represent the natural situation, in which all transcript vari- 
ants might be expressed in a sustainable manner. Altogether epigenetic editing, 
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ATF Artificial transcription factor 
ChIP Chromatin immunoprecipitation 
CpG Cytosine–phosphate–guanine 
CRISPRs Clustered regulatory interspaced palindromic repeats 
DNMT DNA methyltransferase 
ncRNA Nonprotein-coding RNA 
sgRNA Single-guide RNA 
TALEs Transcription activator-like effectors 
TDG Thymidine–DNA glycosylase 
TET Ten–eleven translocation 






The term epigenetics was coined by Conrad Waddington back in 1942, who defined 
epigenetics as the branch of biology that studies the causal interactions between genes 
and their products which bring the phenotype into being (Waddington 2012). This 
definition has evolved over time to the current understanding of epigenetics referring 
to the study of heritable changes in gene expression that occur independent of changes 
in the primary DNA sequence (Sharma et al. 2010). The basic unit of chromatin com- 
prises the nucleosome, which consists of approximately 146 base pairs (bps) of DNA 
wrapped around an octamer containing two copies of each of the core histones H2A, 
H2B, H3, and H4. Biochemical modifications on DNA and histones, as well as the 
nuclear context, influence the three-dimensional structure of chromatin. The main 
covalent chemical modification on DNA itself is the methylation of cytosines at sites 
where it is followed by a guanine base (CpGs). Additionally, posttranslational histone 
modification (PTMs), nucleosome positioning, and the expression of nonprotein- 
coding RNAs (ncRNAs) are important epigenetic modifications. 
A huge number of data has been generated on how epigenetics regulate gene 
expression; however, the majority of these data are only correlative in nature. In 
order to study the causative role of a particular epigenetic modification at a given 
genomic site, epigenetic editing approaches have been exploited in the recent years 
(de Groote et al. 2012; Jurkowski et al. 2015). Epigenetic editing refers to the tech- 
nology of actively rewriting epigenetic signatures at a genomic locus of interest. 
Toward this end, molecular tools – mostly developed and used in genome engineer- 
ing (Gaj et al. 2013) – have been employed that allow DNA binding at a predefined 
genomic locus (Kungulovski and Jeltsch 2015). The most frequently used devices 
for gene targeting are self-engineered zinc finger (ZF) proteins, transcription 
activator-like effectors (TALEs), or the recently introduced clustered regulatory 
interspaced palindromic repeats (CRISPRs) system, which is based on DNA target- 
ing by RNA molecules, the so-called single-guide RNAs (sgRNAs) (Fig. 1). 
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Fig. 1 Schematic representation of the DNA-binding domains of the most commonly used molec- 
ular tools in epigenetic editing. (a) The ZF protein on the left consists of approximately 30 amino 
acids, in which AAs at positions -1, 3, and 6 in the alpha-helix of the ZF protein recognize the third, 
second, and first base pair of the 5’−3’ target sequence. Specificity can be increased by linking 
several ZFs together. The TALEs on the right consist of different monomers of approximately 34 
AAs that are variable at positions 12 and 13 (=RVD), which are responsible for targeting a specific 
base pair within the DNA sequence. Notice that in comparison to the ZF, three times as much AAs 
are responsible for targeting the same amount of base pairs. (b) sgRNAs guide the CRISPR–dCas9 
system to a particular sequence of approximately 20 base pairs. ZF zinc finger, AA amino acid, 
TALE transcription activator-like effector, RVD repeat variable di-residue, sgRNA single-guide 
RNA, CRISPR clustered regulatory interspaced palindromic repeat 
 
ZF proteins are naturally occurring transcription factors forming the largest group 
of all transcription factors in the human genome (Vaquerizas et al. 2009). They 
consist of approximately 30 amino acids, wherein a stretch of seven amino acids is 
responsible for the recognition of 3–4 bps in the major groove of double- stranded 
DNA. During ZF binding, the amino acids at positions -1, 3, and 6 in the alpha-helix 
of the ZF protein recognize the third, second, and first base pair of the 5’−3’ target 
sequence (Fig. 1a, left side). In 1996, Kim and Berg published the crys- tal structure 
of a designed ZF protein, which led to a refinement of this code, because it revealed 
an additional bond between a certain amino acid at position 2 in the ZF alpha-helix 
and the 4th base in the antisense strand of the DNA, which is at the same time the 
complement nucleotide of the 2 triplicate, recognized by amino acid 6 of the second 
ZF protein (Kim and Berg 1996). 
478 S. Stolzenburg et al. 
 
Based on this knowledge, different DNA sequences can be targeted by engineering 
ZF proteins via exchanging amino acids of the α-helix to bind three base pairs of choice 
(Vandevenne et al. 2013). The specificity of ZF proteins is subsequently increased by 
linking several ZF domains together, so that, for example, a six-finger ZF protein will 
recognize 18 base pairs of target DNA (Fig. 1a, left side). When generating these ZF 
arrays, the selection procedure strongly determines the potency, and target site overlap 
or cross talk may complicate the array generation (Mussolino et al. 2011). 
In 1994, Klug and colleagues engineered the first ZF protein successfully target- 
ing and repressing the BCR–ABL fusion oncogene (Choo et al. 1994). Since this 
pioneering work was conducted, engineered ZF proteins have been used in fusion 
with nucleases (molecular scissors) or transcriptional activators and repressors (arti- 
ficial transcription factors, ATFs) to target a multitude of endogenous genes (de 
Groote et al. 2012). The relatively small size and low immunogenicity of ZF proteins 
are a major advantage compared to other DNA-targeting proteins (Falahi et al. 2015; 
Mussolino et al. 2011). Importantly, the potential of ZF proteins as molecular scis- 
sors for therapeutic applications is explored in clinical trials (Ledford 2011). 
TALEs are derived from plant pathogenic bacteria where they are used to modu- 
late host gene expression (Boch and Bonas 2010). Upon injection into the plant 
cells, TALEs are imported into the nucleus where they bind specific sequences of 
the host cell genome and activate transcription. Like ZFs, TALEs also consist of 
individual modules (Jurkowski et al. 2015): each monomer (of 33 or 34 amino acids) 
differs at amino acid positions 12 and 13, a region called repeat variable di- residue 
(RVD) (Fig. 1a, right side). These hypervariable residues mediate binding to the 
target DNA site. Each RVD recognizes one nucleotide within the DNA-binding site 
(HD=C, NI=A, NG=T, NN=G), allowing for a straightforward design. 
Subsequently, transcriptional activators, repressors, or nucleases can be fused to the 
TALE DNA-binding domain (DBD) for targeted gene expression modification. 
Targeting efficiencies of the TALE DBD range from 25 to 95 % (Miller et al. 2011; 
Maeder et al. 2013b), and new assembly methods are now available to improve the 
generation of more efficient TALEs (Reyon et al. 2012; Briggs et al. 2012). 
Considerable progress has been made in the design, development, and characteriza- 
tion of TALEs (Cermak et al. 2011). 
Another breakthrough technology was introduced early in 2013 the flexible 
CRISPRs–CRISPR-associated proteins (CRISPR–Cas) system, which revolution- 
ized biomedical research because of its ease, low cost, and flexibility (Fig. 1b). This 
system is derived from the bacterial defense system where the CRISPR–Cas system 
recognizes foreign DNA and the nuclease activity of Cas9, which is guided to a 
particular sequence by sgRNAs, cleaves the invading DNA. However, in order to 
modulate gene expression without altering the DNA sequence, the endonuclease 
activity of Cas9 is inactivated and instead linked to transcriptional or epigenetic 
modulators (CRISPR–dCas9) (Sander and Joung 2014). 
To summarize, all three systems have in common a programmable DNA-binding 
platform, designed to recognize a specific genomic DNA sequence. Subsequently, for 
epigenetic editing, an epigenetic modulator (or a catalytic domain thereof) is recruited 
to the locus of interest by tethering the effector domain to the DNA-binding platform, 










Fig. 2 Epigenetic editing is used to actively rewrite epigenetic signatures at a genomic location of 
interest. The molecular tools used for this purpose consist of (a) a DNA-binding platform to rec- 
ognize the target sequence (see Fig. 1) and (b) an epigenetic modulator (or a catalytic domain 




either directly (to ZF proteins or TALEs) or to the catalytically inactive Cas9 protein 
(which is recruited by sgRNAs). Upon delivery into target cells, the DNA-binding 
platform finds its DNA sequence, so the epigenetic modulator can expose its enzy- 
matic activity at the desired genomic site (see Figs. 1 and 2). The epigenetic editing 
approach faced much disbelief in its early days, as the epigenetic marks were not 
generally considered to be instructive for gene expression, and if so, it was expected 
that their effect would be overruled by the native chromatin environment on a longer 
term. Moreover, the generally accepted inaccessibility of heterochromatic genes was 
thought to hamper successful editing of silenced genes. Pioneering studies by us and 
others and the introduction of straightforward DNA-targeting approaches set the stage 
for the recent boom in epigenetic editing (Jurkowski et al. 2015). 
The by far most studied epigenetic mark is DNA methylation. It predominately 
occurs on cytosine followed by a guanine (CpG) sites; however, also non-CpG meth- 
ylation has been detected in stem cells (Lister et al. 2009) and in the brain (Lister et 
al. 2013). In promoter regions, CpG dinucleotides often cluster in so-called CpG 
islands (CGIs), and more than half of the human gene promoters contain a CGI 
(Ehrlich et al. 1982; Saxonov et al. 2006). These CpG-rich promoters are usually 
unmethylated, with a few exceptions, including tissue-specific methylation during 
development (Bird et al. 1985; Song et al. 2005). Gene promoters found with high 
levels of DNA methylation are generally transcriptionally inactive (Boyes and Bird 
1992; Siegfried et al. 1999; Jones and Takai 2001). Epigenetic editors will be very 
helpful to investigate whether methylation precedes gene inactivation or whether it is 
rather a consequence of inactivation, since (de)methylation can now be induced at 
will at specific genomic sites. This will also shed light on the order of events during 
the process of DNA methylation at, e.g., promoters, gene bodies, or enhancers. 
 
2 Targeted DNA Methylation 
 
Pioneering work in the field of targeted DNA methylation has been performed by 
Xu and Bestor who were the first to use a fusion protein consisting of an engineered 
ZF protein and a DNA methyltransferase to target DNA methylation to a predefined 
B 
A 
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DNA sequence (Xu and Bestor 1997). Several other studies of targeted DNA meth- 
ylation using ZF proteins fused to human or bacterial DNA methyltransferases have 
been published, showing that the induction of DNA methylation indeed results in 
transcriptional repression (Smith and Ford 2007; Li et al. 2006, 2007; Minczuk    et 
al. 2006; Smith et al. 2008; Carvin et al. 2003; McNamara et al. 2002; van der Gun 
et al. 2010). However, these early studies have only been performed on exog- enous 
or nonmammalian sites. Endogenous gene repression by targeted DNA meth- ylation 
was shown for the first time, in 2012 for the human gene promoters of VEGF-A 
(Siddique et al. 2012) SOX2 and MASPIN (Rivenbark et al. 2012). Both studies used 
designed ZF proteins, engineered to bind a stretch of 18 bps within the promoter of 
the intended target gene. The ZF proteins were fused to the catalytic domain of the 
murine and human DNA methyltransferase 3A (DNMT3A) and a fusion of murine 
Dnmt3a or human DNMT3L, respectively. 
The mouse Dnmt3a fusion resulted in a mean yield of 14.4 % DNA methylation 
over all CpG sites at the interrogated region of the VEGF-A promoter leading to a 
downregulation of mRNA expression by 36 % (Siddique et al. 2012). For certain 
CpGs, the induced methylation even reached efficiencies of 100 %. This average 
effect was further improved – up to a mean of 28.6 % DNA methylation and 56 % 
VEGF-A mRNA downregulation – when the effector domain consisted of the C-
terminal domain of Dnmt3a fused to DNMT3L. This finding further proved that 
DNMT3L stimulates de novo methylation through Dnmt3a, as DNMT3L has no 
catalytic activity itself (Gowher et al. 2005). 
Targeted DNA methylation of the tumor suppressor gene MASPIN using the 
catalytic domain of the human DNMT3A (598–908 amino acids) increased DNA 
methylation up to 60 % at single CpGs within the MASPIN promoter (Rivenbark et 
al. 2012). Increase of DNA methylation was detectable up to 500 bps downstream of 
the ZF target site and translated into a 50 % downregulation of mRNA and protein 
expression compared to an empty vector control. As expected, the downregulation 
of the tumor suppressor gene resulted in an increased proliferation rate and a more 
aggressive phenotype of breast cancer cells in vitro. In addition, the transcription 
factor SOX2 was targeted using an inducible ZF–DNMT3A fusion (Rivenbark et al. 
2012). Cell lines were stably transduced with the ZF–DNMT3A fusion, and as a 
control the same ZF protein fused to the transient repressor SKD (Kruppel- 
associated box domain) was used. This system is induced upon addition of doxycy- 
cline (Dox) to the culture medium, which causes expression of the fusion proteins. 
In turn, discontinuation of the Dox treatment led to depletion of ZF–DNMT3A and 
ZF–SKD expression, respectively. The expression of the SOX2-targeted ZF– 
DNMT3A construct translated into a 60–80 % downregulation of mRNA and pro- 
tein expression, respectively. In a subsequent cell proliferation assay, the ZF–SKD 
construct was included as a control and both, ZF–SKD and ZF–DNMT3A, were 
initially able to decrease cell growth. However, when Dox was removed from the 
culture media 48 h after induction, only the ZF–DNMT3A fusion was able to atten- 
uate cell proliferation over the time course of the experiment, suggesting stable gene 
repression mediated by DNA methylation, although DNA methylation at the SOX2 
promoter was not directly shown (Rivenbark et al. 2012). In a follow-up study, the 
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same lab showed that the silencing of SOX2 expression was indeed mediated by 
targeted DNA methylation (Stolzenburg et al. 2015). Furthermore, depletion of Dox 
and subsequent discontinuation of the expression of the ZF–SKD and ZF–DNMT3A 
fusions led to the re-expression of SOX2 only in ZF–SKD-transduced cells but not 
in cells that previously expressed the DNMT3A construct. Therefore, in this con- 
text, DNMT3A was a more stable mediator of expression than the SKD. Interestingly, 
SOX2 mRNA and protein repression was stronger 8 days after Dox removal than the 
initial downregulation, suggesting that DNA methylation is reinforced by cellular 
mechanisms during subsequent cell divisions. 
Using the mouse Dnmt3a fused to a ZF protein targeting the cell adhesion mol- 
ecule EpCAM (van der Gun et al. 2013), an increase in DNA methylation at the 
endogenous EpCAM promoter by 20–25 % after transient transfection of an ovarian 
cancer cell line was observed (Nunna et al. 2014). At specific CpGs an increase of 
DNA methylation of more than 80 % was detected. In addition, two cell lines were 
generated that stably express ZF–Dnmt3a. Importantly, both cell lines showed an 
increase of DNA methylation at the EpCAM promoter of more than 40 %. The 
induction of promoter DNA methylation decreased the expression of EpCAM 
mRNA (60–70 %) and protein (50 %) in the examined cell line, and furthermore, the 
reduction of EpCAM expression translated into a decrease of the proliferative char- 
acter of the examined ovarian cancer cell line. 
Researchers have also employed TALEs for targeted DNA methylation studies, 
fused to either DNMT3A (Li et al. 2015) or DNMT3A–DNMT3L (Bernstein et al. 
2015), targeting the promoters of CRMP4 and CDKN2A, respectively. Both studies 
successfully showed induced DNA methylation at their respective TALE target 
sites. In both studies, the DNA methylation was associated with target gene repres- 
sion and resulted in the intended physiological downstream effects. Although for 
the CRMP4 promoter, DNA methylation only increased to about 5.5 % upstream to 
6.4 % downstream of the TALE target site (numbers represent mean values of the 
interrogated region, with peaks of max 9–12 % at individual CpGs). The induced 
methylation, however, was sufficient to virtually completely knock down mRNA 
and protein expression in a nonmetastatic prostate cancer cell line (Li et al. 2015). 
This targeted DNA methylation was then shown to spread over 300 bps up- and 
downstream of the TALE–DNMT3A binding site. Importantly, the downregulation 
of CRMP4, a metastasis suppressor gene in a nonmetastatic cell line, led to the for- 
mation of metastasis in vivo. Furthermore, the crucial impact of DNA methylation 
at the CRMP4 promoter for prostate cancer patients’ survival was shown by DNA 
methylation analysis of prostate cancer specimen. The analysis revealed that 64 % 
of CRMP4 methylation positive samples were indeed confirmed as metastatic. 
Bernstein et al. (2015) engineered a TALE–Dnmt3a–DNMT3L (TALE–DNMT) 
construct to target the CDKN2A locus in HeLa cells, primary human fibroblasts, and 
coronary artery smooth muscle cells. The CDKN2A locus encodes the cyclin- 
dependent kinase inhibitor p16, a tumor suppressor, which is regulated by DNA 
methylation. The induced DNA methylation across the CDKN2A CpG island varied 
between 10 % (human fibroblasts) and 13.8 % (HeLa cells) after lentiviral transduc- 
tion and 17 % in HeLa cells after sorting for successfully transfected cells. At 
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individual CpGs, the methylation levels increased even up to 66 % in the sorted 
population after transfection and 30–50 % after lentiviral transduction. The TALE– 
DNMT3A-mediated DNA methylation was associated with a 50 % decrease in p16 
mRNA expression in human fibroblasts accompanied by an increase in cell cycle 
progression. Recently, another group demonstrated ZF-induced methylation of the 
CDKN2A locus to promote migration and invasion of cancer cells (Cui et al. 2015). 
These publications demonstrate that induction of endogenous DNA methylation 
at will by epigenetic editing tools at a specific target is not only possible but also 
effective, as treatment results in the intended physiological downstream effects. The 
induced DNA methylation needed to downregulate gene expression varied highly 
between the studies, and in one case as little as 10 % was sufficient to achieve target 
gene suppression. This strengthens the notion that a single CpG can be crucial for 
gene regulation at a given locus (Pogribny et al. 2000). 
 
3 Stability of the Induced DNA Methylation Changes 
 
It is well documented that promoter DNA methylation plays an important role in 
permanent gene silencing and that established DNA methylation is maintained dur- 
ing cell divisions to achieve stable gene repression (Riggs 1975; Holliday and Pugh 
1975; Lister et al. 2009; Chen et al. 2007; Stein et al. 1982). However, nowadays it 
is presumed that DNA methylation by itself might not be enough to maintain stable 
gene repression in any given context. It is much more agreed that DNA methylation 
and a myriad of additional epigenetic mechanisms, such as histone modifications, 
nucleosome positioning, ncRNAs, and others, work together to create a stable 
context-dependent gene repression pattern (Raynal et al. 2012). Epigenetic editing 
provides unique tools to address sustainability of DNA methylation in different 
chromatin contexts. 
The first study to address maintenance of written DNA methylation marks was 
performed by the Blancafort team. Toward this end, engineered ZF proteins target- 
ing the MASPIN gene were fused to DNMT3A and retrovirally delivered into breast 
cancer cells (Rivenbark et al. 2012). The downregulation of the tumor suppressor 
MASPIN would lead to a more aggressive phenotype of the host cells. To prove this 
hypothesis, retrovirally transduced cells were seeded in soft agar for colony forma- 
tion. After colonies were formed (several weeks later), single colonies were picked 
from the soft agar, disrupted, and cultured for subsequent sodium bisulfite sequenc- 
ing to investigate the methylation state of MASPIN. The data revealed that even  50 
days post-transduction DNA, methylation was maintained in the host cells 
(Rivenbark et al. 2012). Interestingly, knockdown of UHRF1 (ubiquitin-like con- 
taining PHD and RING finger domains 1, a protein required for the maintenance of 
DNA methylation patterns (Bostick et al. 2007; Sharif et al. 2007)) led to re- 
expression of MASPIN in these cells (Rivenbark et al. 2012). 
The longevity of the induced DNA methylation was further tested in vivo for the 
SOX2 promoter in a xenograft mouse model (Stolzenburg et al. 2015). To do so, the 
advantages of the Dox-inducible system were exploited: the Dox-inducible system 
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allows controlled expression of the ZF–DNMT3A fusion by administration of a 
Dox-containing diet, whereas the switch to a Dox-free diet leads to the discontinu- 
ation of the ZF–DNMT3A expression. The results showed a strong tumor growth 
inhibition in the cells that expressed the ZF–DNMT3A fusion. This was associated 
with DNA methylation at the SOX2 promoter together with a decrease in SOX2 
expression. Although DNA methylation at the SOX2 promoter was largely sustained 
for 53 days post-Dox removal, after the removal of ZF–DNMT3A expression, 
tumor growth inhibition was only maintained for 10 days. Interestingly, examination 
of ZF–DNMT3A and SOX2 expression at day 10 after Dox removal revealed a 
maintained repression of SOX2 and no detection of ZF–DNMT3A, implying – once 
being induced – a long-term effect of DNA methylation on SOX2 repression. 
However, to truly verify the long-term effect of written DNA methylation signa- 
tures, DNA methylation and target gene expression should be validated at later time 
points. This notion is underpinned by a recent publication showing that ZF-targeted 
DNA methylation at the VEGF-A promoter by means of transient adenoviral trans- 
fer was not stably maintained (Kungulovski et al. 2015). The authors examined, after 
targeting a ZF–DNMT3A fusion to the VEGF-A promoter, the longevity of the 
induced DNA methylation mark at the VEGF-A promoter and VEGF-A expression 
over a time course of 15 days. In contrast to Stolzenburg et al., the loss of experi- 
mental ZF–DNMT3A expression was associated with a loss of DNA methylation at 
the target site and target gene re-expression (Kungulovski et al. 2015). Interestingly, 
the authors also looked into secondary effects of the induced DNA methylation on 
histone modifications. After induction of the targeted DNA methylation at the 
VEGF-A promoter, the authors examined whether the methylation mark at the DNA 
level is reinforced by a change in the silencing mark H3K9me3. However, no 
changes in H3K9me3 were detected using ChIP–qPCR (Kungulovski et al. 2015). 
As epigenetic editing is uniquely suited to address the parameters allowing or pre- 
venting maintenance of DNA methylation, ongoing research efforts are expected to 
yield important insights in this respect. 
 
 
4 Targeted DNA Demethylation 
 
Epigenome-wide association studies result in increasing lists of aberrantly hyper- 
methylated loci associated with various clinical phenotypes. Mimicking these meth- 
ylation profiles by epigenetic editing will provide valuable insights into the 
biological function of these modifications. More importantly, the actual removal of 
such epimutations will open new therapeutic avenues. Indeed, in the clinical setting, 
inhibitors of DNA methyltransferases are used to prevent hypermethylation of 
tumor suppressor genes. Unfortunately, such conventional epigenetic drugs will 
affect methylation patterns genome-wide. In contrast, epigenetic editing approaches 
might exploit the reversibility of epigenetic marks in a gene-targeted manner and in 
this way avoid potentially dangerous side effects. 
Before the identification of active DNA methylation-modifying enzymes, DNA 
repair mechanisms were exploited for their role in reducing local DNA methylation 
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profiles. Indeed, Gregory et al. reported that the targeting of thymidine–DNA gly- 
cosylase (TDG) by fusion to engineered ZF proteins did result in lowering of DNA 
methylation, allowing improved induction of the target gene Nos2 (Gregory et al. 
2013). The identification of ten–eleven translocation (TET) enzymes and their role 
in modifying methylated cytosines allowed epigenetic editing approaches to actively 
reduce hypermethylation states of target genes without introducing temporary 
changes to the DNA. Indeed, we were the first group to report on the potency of 
targeting the TET domains to induce active DNA demethylation (Rots and Petersen- 
Mahrt 2013; Chen et al. 2014). Targeting either of the three TET members to the 
hypermethylated ICAM gene demonstrated that both TET1 and TET2 are effective 
reducers of DNA methylations. Although DNA demethylation in this experimental 
setting was relatively low (minus ca 5 approx.), gene expression was increased two- 
fold. Obviously, when compared to targeting of VP64, a strong viral transcription 
activator, this gene expression modulation was modest. However, such mild 
increases might be physiologically more relevant, and these findings do generate 
opportunities to realize therapeutically relevant localized DNA demethylation. 
Indeed, we confirmed the robustness of the TET2-targeting approach in inducing 
DNA demethylation for four other genes (EPB41L3, C13ORF18, CCNA1, and 
TFPI2; all putative hypermethylation biomarkers for cervical cancer) (Huisman   et 
al. 2015a; Huisman et al. 2015b). Although the observation that modest local 
demethylation is less effective in gene re-expression than targeting a transcriptional 
activator is understandable, the large size of TET domains is also partially respon- 
sible for this effect. Interestingly, when cells were co-treated with the epigenetic 
drug trichostatin A (TSA), which is a histone deacetylase inhibitor that might 
increase gene accessibility, induced expression of silenced target genes was detect- 
able (Huisman et al. 2015a). 
Despite the large size of the TET domain, also in fusion with the relatively larger 
TALE domains, TET1 was able to induce targeted DNA  demethylation (Maeder  et 
al. 2013a; Li et al. 2015). Maeder et al. were the first to show targeted demethyl- 
ation using TALEs fused to TET1. In total, they engineered 25 TET1-containing 
TALEs targeting KLF4, HBB, and RHOXF2 (Maeder et al. 2013a). Comparison of 
the TALE constructs – either fused to the full-length TET1 or the constructs con- 
taining only the TET1 catalytic domain (TET1c) – showed that the catalytic domain 
had a stronger effect on demethylating its target genes (up to 30 % at KLF4 and even 
84 % at HBB) than the full-length TET1 (Maeder et al. 2013a). The most effective 
demethylation was observed within 30 bps up- and downstream but also up to   200 
bps away from the target sequence. This is in accordance with a study published by 
Li et al., who examined two regions located 4 bps upstream and 95 bps down- stream 
of the TALE–TET1c target site for their methylation status. Both regions showed 
demethylation with the more distant region being more efficiently demeth- ylated. 
In this study, DNA demethylation was associated with a re-expression of target gene 
mRNA expression, followed by an induction of protein expression (Li et al. 2015). 
As expected, the demethylation and re-expression of CRMP4 (a metas- tasis 
suppressor gene) showed a decrease in migration and invasion in otherwise 
metastatic cell lines. Furthermore, the re-expression of CRMP4 after active DNA 
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demethylation abolished the metastatic character of these cells even in an in vivo 
mouse model of prostate cancer (Li et al. 2015). However, demethylation of the 
target gene by TALE–TET1c did not always result in induced gene expression. Only 
four out of ten demethylating TALE–TET1c constructs targeting HBB indeed 
increased the expression of HBB mRNA. Similarly, in the case of RHOXF2, two out 
of five demethylating TALEs–TET1c induced mRNA expression (Maeder et al. 
2013a). The authors suggested that the artificial demethylation at the target gene 
was not stably transmitted, and therefore, demethylated CpGs became remethyl- 
ated, as TALE–TET1c coding constructs became cleared from the transfected cells. 
A very interesting aspect of the targeted DNA demethylation, namely, its effect   
on histone modifications, was examined by Li et al. for both regions that showed a 
decrease in TALE–TET1c-mediated DNA methylation (Li et al. 2015). While the 
region directly upstream to the TALE–TET1c target site showed a reduction of 
repressive histone modifications (H3K9me3, H3K27me3, H3K79me3), this was not 
seen at the region 95 bps downstream of the target site, although this region showed 
stronger demethylation (Li et al. 2015). 
 
5 Concluding Remarks and Future Perspectives 
 
Epigenetics has been receiving a lot of attention in this post-genomic era: many 
abnormalities in the epigenetic landscape have been identified in numerous dis- 
eases, and so-called epigenetic drugs, including inhibitors of DNA methyltransfer- 
ase, have entered the clinical arena. Epigenetic editing – to mimic or reverse such 
epimutations – is currently gaining widespread acceptance, and many research 
groups join the field. Initially, the technology had to overcome some hurdles: 
genome specificity was not likely to be achieved, accessibility of silenced genes was 
thought to be impossible, and the instructive nature of epigenetic marks with respect 
to controlling gene expression was highly questioned. As reviewed here, these 
assumptions have been proven untrue. To increase the specificity of targeting, a 
considerable progress has been made in the field of enzyme engineering, where split 
enzymes allow activity to take place only when two split parts are brought close 
together via their fusion to two closely binding DNA-targeting modules (Kiss and 
Weinhold 2008). Genome-wide specificity can also be achieved using CRISPR– 
dCas9 technology (Hilton et al. 2015), and the progress in sgRNA design is expected 
to rapidly improve our understanding of the off-target effects. Taken together, this 
allows the prediction and prevention of unwanted side effects due to unintended 
endogenous binding. 
Also – against common belief – heterochromatin is not hampering accessibility per 
se, as re-expression of silenced genes has now been shown for many heterochromatic 
genes (tumor suppressors) by ATFs (Beltran et al. 2007; Lara et al. 2012; van der Wijst 
et al. 2015; Falahi et al. 2013; Huisman et al. 2013) and epigenetic editors (e.g. Chen 
et al. 2014; Huisman et al. 2015a, b). Although the transcriptional activators/ 
repressors in ATFs are relatively small in size, also larger constructs can gain gene 
access even though size is likely to affect effectiveness for heterochromatic genes. 
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On top of that, the heterochromatin landscape, which is unique for each gene and 
cell, needs further investigation in order to completely understand the mechanism of 
action of different epigenetic editors. 
With respect to the cause versus consequence relationship of epigenetic marks and 
gene expression, strong indications that epigenetics is instructive in gene expression 
regulation have been obtained by targeting effector domains to artificial loci (e.g., 
plasmids and integrated sites) as reviewed by us in 2012 (de Groote et al. 2012). At 
that time, only two examples were published, which confirmed that editing of epigen- 
etic marks at a predetermined endogenous site was effective in modulating gene 
expression (Snowden et al. 2002; Rivenbark et al. 2012). These days, epigenetic/epig- 
enome editing has been declared a method to watch (Rusk 2014), and a rapid increase 
in publications confirms efficiency of the approach (Ledford 2015). An important 
open question concerns the chromatin microenvironment conditions allowing sus- 
tained re-expression, but the technology of epigenetic editing is uniquely qualified to 
address this question (Cano-Rodriguez et al. 2016). As also the CRISPR–dCas9 plat- 
form is currently exploited for targeted (de)methylation (Choudhury et al. 2016; 
McDonald et al. 2016; Vojta et al. 2016; Xu et al. 2016), we expect epigenetic editing 
tools to soon reprogram the genome in a sustained manner, which will provide a clini- 
cally relevant hit-and-run approach to cure currently incurable diseases, including 
imprinting (Bashtrykov et al. 2015) or behavioral disorders (Dekker et al. 2014). 
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